NCT06639607View on ClinicalTrials.gov

PEP-CMV + Nivolumab for Newly Diagnosed Diffuse Midline Glioma/High-grade Glioma and Recurrent Diffuse Midline Glioma/High-grade Glioma, Medulloblastoma, and Ependymoma

PHASE1/PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

68

Participants

Timeline

Start Date

November 30, 2025

Primary Completion Date

January 31, 2031

Study Completion Date

November 30, 2042

Conditions
Diffuse Midline GliomaDiffuse Midline High-grade GliomaMedulloblastomaEpendymoma
Interventions
BIOLOGICAL

PEP-CMV vaccine

Intra-dermally administered half in the RIGHT groin and half in the LEFT groin.

BIOLOGICAL

Tetanus booster

Td 5 flocculation units, Lf

BIOLOGICAL

Nivolumab

Administered intravenously

DRUG

Temozolomide

Administered orally

Trial Locations (3)

27710

Duke University Medical Center, Durham

63110

Washington University School of Medicine, St Louis

77030

MD Anderson Cancer Center, Houston

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

Washington University School of Medicine

OTHER

NCT06639607 - PEP-CMV + Nivolumab for Newly Diagnosed Diffuse Midline Glioma/High-grade Glioma and Recurrent Diffuse Midline Glioma/High-grade Glioma, Medulloblastoma, and Ependymoma | Biotech Hunter | Biotech Hunter